AKBA – Akebia Therapeutics: Buy This Undervalued Stock At Just 77% Of Revenue

Anterior or front xray view of the kidneys and the ureter 3D rendering illustration with male body contours. Human anatomy, medical, biology, science, healthcare concepts.

libre de droit

In agreement with Seeking Alpha Quant, I rate Akebia Therapeutics, Inc. (NASDAQ:AKBA) a Strong Buy on the basis of its overly discounted revenue, which has strong prospects in a very large Chronic Kidney Disease, or CDK, Total Addressable Market, or TAM. AKBA is